Swedish biotechnology company Cantargia AB (STO:CANTA) on Monday reported early results from an ongoing Phase 1b/2a trial evaluating nadunolimab in combination therapies for high-risk myelodysplastic syndrome (MDS) and acute myelogenous leukaemia (AML).

The study combines nadunolimab with azacitidine in MDS and with azacitidine and venetoclax in AML.

The Phase 1b dose-escalation stage has been completed, involving six patients in each cohort, with the trial now advancing to Phase 2a. Treatment was generally well tolerated across both groups, with an acceptable safety profile.

In the high-risk MDS cohort, five of six patients were evaluable for efficacy, with all five achieving complete remission, while one remains pending assessment. The preliminary data indicate a potential signal of clinical activity for nadunolimab in combination with standard-of-care therapies in haematologic malignancies.

The trial is led by Gautam Borthakur at The University of Texas MD Anderson Cancer Center, with further updates expected later in 2026 as enrolment progresses toward approximately 40 patients.